Business Can Breyanzi be a hit CAR-T in second-line treatment after failing in the first-line setting for the patients with R/R Large B-cell lymphoma (LBCL)? ByHaven smith July 14, 2022
Business Primary Hyperoxaluria Market Insight, Epidemiology And Market Forecast – 2032 ByHaven smith July 13, 2022
Business The PROs Further Support Durvalumab + Chemo in Becoming The New Standard of Care in 1st Line Advanced Biliary Tract Cancer ByHaven smith July 13, 2022
Business ASCO Conference Highlights: Metastatic Colorectal Cancer, Bladder Cancer ByHaven smith July 8, 2022
Business Making Way For Immunotherapy In The GI Cancers, Durvalumab To Become The New Standard of Care For Advanced Biliary Tract Cancers ByHaven smith July 7, 2022
Business Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology And Market Forecast – 2032 ByHaven smith July 6, 2022
Business With modest efficacy, Neratinib Continues To Be A Potential Treatment Option For HER2+ive Biliary Tract Cancers ByHaven smith July 5, 2022
